ThromboGenics has received FDA approval for a drug to treat symptomatic vitreomacular adhesion, according to a news release.
The drug, Jetrea, is approved to treat the eye condition, which can contribute to problems if the vitreous starts to move away from the macula. This movement can lead to damage of the macula due to pulling or tugging on the macula.
Jetrea is an enzyme that breaks down proteins in the eye responsible for vitreomacular adhesion.
"Today's approval represents a significant advancement in treatment for patients with symptomatic vitreomacular adhesion," said Edward Cox, MD, MPH, director of the office of antimicrobial products in FDA's Center for Drug Evaluation and Research, in the release. "Those with this sight-threatening disease now have a non-surgical treatment option."
ThromboGenics is headquartered in Iselin, N.J.
Related Articles on FDA Clearances:
Loma Vista Medical Receives FDA Clearance for Balloon Valvuloplasty Catheter
EarlySense Receives FDA Clearance for Patient Monitoring System
Kelyniam Receives FDA Clearance for Craniofacial Implants